----
Current ValuationThe current P/E ratio is 30.28, below the reasonable range, cheaper than 89.66% of the time in the past 1 years, and the industry ranks 49/605, the industry Median -1.87.
30.28xP/E
$43.12Stock price
$1.42Earnings per share
30.28xP/E
Stock price$43.12Earnings per share$1.42
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 43.34x
- Typical range
- 32.33x–108.39x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
021426384
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BIIBUSBiogen | 41.19x | 29.97% | $34.37B |
ALNYUSAlnylam Pharma | 40.04x | 185.32% | $31.02B |
HALOUSHalozyme Therap | 33.44x | 185.16% | $13.83B |
KRYSUSKrystal Biotech | 38.81x | 7.46% | $9.37B |
VCYTUSVeracyte | 30.28x | 35.02% | $3.47B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
